|Awaiting full HTA submission from Applicant
|Fenfluramine (Fintepla®) is indicated for seizures associated with Dravet Syndrome (as an add-on therapy for patients two years of age and older).
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of fenfluramine compared with the current standard of care.
|Full pharmacoeconomic assessment commissioned by HSE
|Pre-submission consultation with Applicant